Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
18 "Sung Whan Ha"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Articles
Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study
Younak Choi, Do-Youn Oh, Kyubo Kim, Eui Kyu Chie, Tae-Yong Kim, Kyung-Hun Lee, Sae-Won Han, Seock-Ah Im, Tae-You Kim, Sung Whan Ha, Yung-Jue Bang
Cancer Res Treat. 2016;48(3):1045-1055.   Published online October 16, 2015
DOI: https://doi.org/10.4143/crt.2015.226
AbstractAbstract PDFPubReaderePub
Purpose
The optimal treatment strategy for locally advanced pancreatic cancer (LAPC), particularly the role of concurrent chemoradiotherapy (CCRT), remains debatable. We compared the clinical outcomes of CCRT and palliative chemotherapy alone (CA) in patients with unresectable LAPC. Materials and Methods Patients with LAPC who were consecutively treated between 2003 and 2010 were included. Resectability was evaluated according to National Comprehensive Cancer Network ver. 1.2012. The clinical outcomes for each treatment group (CCRT vs. CA) were evaluated retrospectively.
Results
Sixty-three patients (58.9%) and 44 patients (41.1%) were treated with CCRT and CA, respectively. The CCRT cohort included patients who were treated with CCRT with or without chemotherapy backbone (CCRT alone, induction chemotherapy-CCRT, CCRT-maintenance chemotherapy, and induction-CCRT-maintenance chemotherapy). Median progression-free survival (PFS) and overall survival (OS) of all patients were 7.2 months and 13.1 months. PFS of the CCRT and CA groups was 9.0 months and 4.4 months, respectively (p=0.020). OS of the CCRT and CA groups was 15.4 months and 9.3 months, respectively (p=0.011). In multivariate analysis, the adjusted hazard ratio of CCRT was 0.536 (p=0.003) for OS and 0.667 (p=0.078) for PFS. Although the pattern of failure was similar in the CCRT and CA groups, the times to both local and distant failure were significantly longer in the CCRT group. Conclusion In patients with unresectable LAPC, those who underwent CCRT during their entire treatment courses had longer OS than patients treated with chemotherapy alone.

Citations

Citations to this article as recorded by  
  • Dose-Escalated SBRT for Borderline and Locally Advanced Pancreatic Cancer: Resectability Rate and Pathological Results of a Multicenter Prospective Study
    Barbara Salas-Salas, Laura Ferrera-Alayon, Alberto Espinosa-Lopez, Maria Luisa Perez-Rodriguez, Antonio Alayón Afonso, Andres Vera-Rosas, Gabriel Garcia-Plaza, Rodolfo Chicas-Sett, Maria Soledad Martinez-Martin, Elisa Salcedo, Andrea Kannemann, Marta Llor
    Cancers.2025; 17(2): 191.     CrossRef
  • Dose-escalated SBRT for borderline and locally advanced pancreatic cancer. Feasibility, safety and preliminary clinical results of a multicenter study
    B. Salas, L. Ferrera-Alayón, A. Espinosa-López, A. Vera-Rosas, E. Salcedo, A. Kannemann, A. Alayon, R. Chicas-Sett, M. LLoret, P.C. Lara
    Clinical and Translational Radiation Oncology.2024; 45: 100753.     CrossRef
  • Survival benefits of radiotherapy in locally advanced unresectable and metastatic pancreatic cancer: a single-institution cohort and SEER database analysis
    Bi-Yang Cao, Le-Tian Zhang, Chen-Chen Wu, Jing Wang, Lin Yang
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Comparing concurrent chemoradiotherapy, 125I seed implantation combined with chemotherapy, and chemotherapy alone efficacy in treating unresectable locally advanced pancreatic cancer
    Yanfen Zheng, Rui Huang, Wenxue Zou, Chao Liu, Hongxin Niu, Jinbo Yue
    Precision Radiation Oncology.2022; 6(2): 144.     CrossRef
  • Concurrent Nab-paclitaxel and Radiotherapy
    William T. Arscott, Kevin T. Nead, Adham Bear, Sriram Venigalla, Jacob Shabason, John N. Lukens, John P. Plastaras, Andrzej Wojcieszynski, James Metz, Mark O’Hara, Kim A. Reiss, Ursina Teitelbaum, Arturo Loaiza-Bonilla, Jeffrey Drebin, Major K. Lee, Stuti
    American Journal of Clinical Oncology.2021; 44(9): 469.     CrossRef
  • Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer
    Mei Hua Jin, Ah-Rong Nam, Ji Eun Park, Ju-Hee Bang, Yung-Jue Bang, Do-Youn Oh
    Cancer Research and Treatment.2020; 52(1): 149.     CrossRef
  • Current trends and issues of conversion surgery for patients with locally advanced unresectable pancreatic cancer
    Toshimichi ASANO, Satoshi HIRANO, Toru NAKAMURA, Takehiro NOJI, Keisuke OKAMURA, Takahiro TSUCHIKAWA, Yuma EBIHARA, Toshiaki SHICHINOHE
    Suizo.2018; 33(1): 48.     CrossRef
  • Survival benefit of conversion surgery for patients with initially unresectable pancreatic cancer who responded favorably to nonsurgical treatment
    Toshimichi Asano, Satoshi Hirano, Toru Nakamura, Keisuke Okamura, Takahiro Tsuchikawa, Takehiro Noji, Yoshitsugu Nakanishi, Kimitaka Tanaka, Toshiaki Shichinohe
    Journal of Hepato-Biliary-Pancreatic Sciences.2018; 25(7): 342.     CrossRef
  • Which patients with locally advanced pancreatic cancer treated with induction chemotherapy are most likely to benefit from post-induction chemoradiotherapy?
    Sophie Otter, Irene Chong, Ria Kalaitzaki, Diana Tait
    International Journal of Hepatobiliary and Pancreatic Diseases.2018; 8(1): 1.     CrossRef
  • Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy
    Yi-Jun Kim, Hyeon Kang Koh, Eui Kyu Chie, Do-Youn Oh, Yung-Jue Bang, Eun Mi Nam, Kyubo Kim
    International Journal of Clinical Oncology.2017; 22(6): 1069.     CrossRef
  • Risk factors of liver metastasis from advanced pancreatic adenocarcinoma: a large multicenter cohort study
    Dong S., Wang L., Guo Y. B., Ying H. F., Shen X. H., Meng Z. Q., Chen Hao, Chen Q. W., Li Z. S.
    World Journal of Surgical Oncology.2017;[Epub]     CrossRef
  • Risk factors for latent distant organ metastasis detected by staging laparoscopy in patients with radiologically defined locally advanced pancreatic ductal adenocarcinoma
    Ilhan Karabicak, Sohei Satoi, Hiroaki Yanagimoto, Tomohisa Yamamoto, Satoshi Hirooka, So Yamaki, Hisashi Kosaka, Kentaro Inoue, Yoichi Matsui, Masanori Kon
    Journal of Hepato-Biliary-Pancreatic Sciences.2016; 23(12): 750.     CrossRef
  • 12,147 View
  • 137 Download
  • 11 Web of Science
  • 12 Crossref
Close layer
Effect of Time Interval between Breast-Conserving Surgery and Radiation Therapy on Outcomes of Node-Positive Breast Cancer Patients Treated with Adjuvant Doxorubicin/Cyclophosphamide Followed by Taxane
Hyeon Kang Koh, Kyung Hwan Shin, Kyubo Kim, Eun Sook Lee, In Hae Park, Keun Seok Lee, Jungsil Ro, So-Youn Jung, Seeyoun Lee, Seok Won Kim, Han-Sung Kang, Eui Kyu Chie, Wonshik Han, Dong-Young Noh, Kyung-Hun Lee, Seock-Ah Im, Sung Whan Ha
Cancer Res Treat. 2016;48(2):483-490.   Published online June 5, 2015
DOI: https://doi.org/10.4143/crt.2015.111
AbstractAbstract PDFPubReaderePub
Purpose
This study evaluated the effect of surgery-radiotherapy interval (SRI) on outcomes in patients treated with adjuvant radiotherapy (RT) after breast-conserving surgery (BCS) and adjuvant four cycles of doxorubicin/cyclophosphamide (AC) followed by four cycles of taxane. Materials and Methods From 1999 to 2007, 397 eligible patients were diagnosed. The effect of SRI on outcomes was analyzed using a Cox proportional hazards model, and a maximal chi-square method was used to identify optimal cut-off value of SRI for each outcome.
Results
The median SRI was 6.7 months (range, 5.6 to 10.3 months). A SRI of 7 months was the significant cut-off value for distant metastasis-free survival (DMFS) and disease-free survival (DFS) using a maximal chi-square method. For overall survival, a significant cut-off value was not found. The patients with SRI > 7 months had worse 6-year DMFS and DFS than those with SRI ≤ 7 months on univariate analysis (DMFS, 81% vs. 91%, p=0.003; DFS, 78% vs. 89%, p=0.002). On multivariate analysis, SRI > 7 months did not affect DMFS and DFS. Conclusion RT delayed for more than 7 months after BCS and adjuvant four cycles of AC followed by four cycles of taxane did not compromise clinical outcomes.

Citations

Citations to this article as recorded by  
  • MiR-210 regulates lung adenocarcinoma by targeting HIF-1α
    Guolei Cao, Peiwen Fan, Ronghui Ma, Qinghe Wang, Lili He, Haiwen Niu, Qin Luo
    Heliyon.2023; 9(5): e16079.     CrossRef
  • Timing of postmastectomy radiotherapy following adjuvant chemotherapy for high-risk breast cancer: A post hoc analysis of a randomised controlled clinical trial
    Si-Ye Chen, Guang-Yi Sun, Yu Tang, Hao Jing, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Xu-Ran Zhao, Yu-Chun Song, Bo Chen, Shu-Nan Qi, Yuan Tang, Ning-Ning Lu, Ning Li, Hui Fang, Ye-Xiong Li, Shu-Lian Wang
    European Journal of Cancer.2022; 174: 153.     CrossRef
  • Timing of Postmastectomy Radiotherapy Following Adjuvant Chemotherapy for High-Risk Breast Cancer: A Post-Hoc Analysis of a Randomised Controlled Clinical Trial
    Si-Ye Chen, Guang-Yi Sun, Yu Tang, Hao Jing, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Xu-Ran Zhao, Yu-Chun Song, Bo Chen, Shu-Nan Qi, Yuan Tang, Ning-Ning Lu, Ning Li, Hui Fang, Ye-Xiong Li, Shu-Lian Wang
    SSRN Electronic Journal .2022;[Epub]     CrossRef
  • Social Determinants of Racial Disparities in Breast Cancer Mortality Among Black and White Women
    Oluwole Adeyemi Babatunde, Jan M. Eberth, Tisha Felder, Robert Moran, Samantha Truman, James R. Hebert, Jiajia Zhang, Swann Arp Adams
    Journal of Racial and Ethnic Health Disparities.2021; 8(1): 147.     CrossRef
  • How Does the Interval Between Completion of Adjuvant Chemotherapy and Initiation of Radiotherapy Impact Clinical Outcomes in Operable Breast Cancer Patients?
    Lu Cao, Cheng Xu, Gang Cai, Wei-Xiang Qi, Rong Cai, Shu-Bei Wang, Dan Ou, Min Li, Kun-Wei Shen, Jia-Yi Chen
    Annals of Surgical Oncology.2021; 28(4): 2155.     CrossRef
  • Saving the Breast Saves the Lives of Breast Cancer Patients
    Mohammad Esmaeil Akbari, Maryam Khayamzadeh, Hamid Reza Mirzaei, Afshin Moradi, Atieh Akbari, Farid Moradian, Neda Khalili
    International Journal of Surgical Oncology.2020; 2020: 1.     CrossRef
  • Timing of Chemotherapy and Radiotherapy Following Breast-Conserving Surgery for Early-Stage Breast Cancer: A Retrospective Analysis
    Si-Ye Chen, Yu Tang, Shu-Lian Wang, Yong-Wen Song, Hui Fang, Jian-Yang Wang, Hao Jing, Jiang-Hu Zhang, Guang-Yi Sun, Xu-Ran Zhao, Jing Jin, Yue-Ping Liu, Bo Chen, Shu-Nan Qi, Ning Li, Yuan Tang, Ning-Ning Lu, Hua Ren, Zi-Hao Yu, Ye-Xiong Li
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Evaluation of tissue computed tomography number changes and dosimetric shifts after conventional whole-breast irradiation in patients undergoing breast-conserving surgery
    Joo Hwan Lee, Dong Soo Lee, So Hyun Park, Young Kyu Lee, Jeong Soo Kim, Yong Seok Kim
    Tumor Biology.2018; 40(8): 101042831879188.     CrossRef
  • The influence of timing of radiation therapy following breast-conserving surgery on 10-year disease-free survival
    Marissa C van Maaren, Reini W Bretveld, Jan J Jobsen, Renske K Veenstra, Catharina GM Groothuis-Oudshoorn, Hendrik Struikmans, John H Maduro, Luc JA Strobbe, Philip MP Poortmans, Sabine Siesling
    British Journal of Cancer.2017; 117(2): 179.     CrossRef
  • 11,504 View
  • 126 Download
  • 10 Web of Science
  • 9 Crossref
Close layer
A New Isolated Mediastinal Lymph Node or Small Pulmonary Nodule Arising during Breast Cancer Surveillance Following Curative Surgery: Clinical Factors That Differentiate Malignant from Benign Lesions
Tae-Yong Kim, Kyung-Hun Lee, Sae-Won Han, Do-Youn Oh, Seock-Ah Im, Tae-You Kim, Wonshik Han, Kyubo Kim, Eui Kyu Chie, In-Ae Park, Young Tae Kim, Dong-Young Noh, Sung Whan Ha, Yung-Jue Bang
Cancer Res Treat. 2014;46(3):280-287.   Published online July 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.3.280
AbstractAbstract PDFPubReaderePub
Purpose
A newly isolated mediastinal lymph node (LN) or a small pulmonary nodule, which appears during breast cancer surveillance, may pose a diagnostic dilemma with regard to malignancy. We conducted this study to determine which clinical factors were useful for the differentiation of malignant lesions from benign lesions under these circumstances. Materials and Methods We enrolled breast cancer patients who were presented with a new isolated mediastinal LN or small pulmonary nodule that arose during surveillance, and whose lesions were pathologically confirmed. Tissue diagnosis was made by mediastinoscopy, video-assisted thoracic surgery or thoracotomy. Results A total of 43 patients were enrolled (mediastinal LN, 13 patients; pulmonary nodule, 30 patients). Eighteen patients (41.9%) were pathologically confirmed to have a benign lesion (benign group), and 25 patients (58.1%) were confirmed to have malignant lesion (malignant group). Between the two groups, the initial tumor size (p=0.096) and N stage (p=0.749) were similar. Hormone receptor negativity was more prevalent in the malignant group (59.1% vs. 40.9%, p=0.048). The mean lesion size was larger in the malignant group than in the benign group (20.8 mm vs. 14.4 mm, p=0.024). Metastatic lesions had a significantly higher value of maximal standardized uptake (mSUV) than that of benign lesions (6.4 vs. 3.4, p=0.021). Conclusion Hormone receptor status, lesion size, and mSUV on positron emission tomography are helpful in the differentiation of malignant lesions from benign lesions in breast cancer patients who were presented with a new isolated mediastinal LN or small pulmonary nodule during surveillance.

Citations

Citations to this article as recorded by  
  • Unusual metastases of breast cancer: a single-center retrospective study
    Pınar ÖZDEMİR AKDUR, Nazan ÇİLEDAĞ
    The European Research Journal.2023; 9(6): 1444.     CrossRef
  • 18Fluorodeoxyglucose‐positron emission tomography/computed tomography features of suspected solitary pulmonary lesions in breast cancer patients following previous curative treatment
    Lei Zhu, Haiman Bian, Lieming Yang, Jianjing Liu, Wei Chen, Xiaofeng Li, Jian Wang, Xiuyu Song, Dong Dai, Zhaoxiang Ye, Wengui Xu, Xiaozhou Yu
    Thoracic Cancer.2019; 10(5): 1086.     CrossRef
  • 12,823 View
  • 60 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
Patterns of Failure after Postoperative Radiation Therapy for Endometrial Carcinoma
Suzy Kim, Hong-Gyun Wu, Hyo-Pyo Lee, Soon-Beom Kang, Yong-Sang Song, Noh-Hyun Park, Sung Whan Ha
Cancer Res Treat. 2006;38(3):133-138.   Published online June 30, 2006
DOI: https://doi.org/10.4143/crt.2006.38.3.133
AbstractAbstract PDFPubReaderePub
Purpose

We tried to investigate the outcome and patterns of failure of endometrial cancer patients who were treated with surgery and postoperative radiation therapy (RT).

Materials and Methods

Eighty-three patients with endometrial cancer who received postoperative RT between May 1979 and August 2000 were included in this retrospective study. Forty-one patients received total abdominal hysterectomy, 41 patients received Wertheim's operation and 1 underwent vaginal hysterectomy. Pelvic lymph node dissection or pelvic lymph node sampling was done in 56 patients and peritoneal cytology was done in 35. All the patients were staged according to 1988 FIGO (International Federation of Gynecology and Obstetrics) staging system; 2 were stage IA, 23 were stage IB, 20 were stage IC, 4 were stage IIA, 5 were stage IIB, 9 were stage IIIA, 2 were stage IIIB and 18 were stage IIIC. The histologic diagnoses were adenocarcinoma in seventy-four patients (89%). The histologic grades were Grade 1, 2 and 3 in 21 (25%), 43 (52%) and 10 (12%) patients, respectively. All the patients received external beam RT (EBRT) with a median dose of 5,040 cGy (range: 4,500~5,075 cGy) to the whole pelvis. Five patients with pathologically confirmed paraaortic lymph node metastasis received 4500 cGy to the paraaortic lymph nodes. Fifteen patients received low-dose intracavitary brachytherapy after their EBRT. A total dose of 7,500~9,540 cGy (median dose: 8511) was prescribed to the vaginal surface.

Results

Overall, 11 patients (13%) experienced disease relapse: 4 with initial stage I or II disease and 7 with initial stage III disease. Among the 54 stage I or II patients, 1 (2%) relapsed in the pelvis only, 2 (4%) relapsed in the vagina and distant organs, and 1 (2%) relapsed in the paraaortic lymph nodes (PANs). Among the 29 stage III patients, 1 (3%) relapsed in the vagina. The most common sites of failure for the stage III patients were the peritoneum (3 patients, 10%), PANs (2 patients, 7%), and lung (2 patients, 7%). With a median follow-up period of 86 months, the overall survival (OS) and disease-free survival (DFS) rates at 5 years were 87% for both. The five-year DFS rate was 93%, 100% and 74% for the stage I, II and III patients, respectively. Three patients experienced severe radiation-related late complications: RTOG (Radiation Therapy Oncology Group) grade 3 radiation cystitis was seen in one patient, and grade 3 bowel obstruction was seen in two patients.

Conclusions

Postoperative RT was useful for controlling pelvic disease. The major patterns of failure for stage III patients were peritoneal seeding and distant metastasis. Selective use of whole abdominal radiotherapy or adjuvant chemotherapy may improve the therapeutic outcome of these patients.

Citations

Citations to this article as recorded by  
  • Pattern of care and clinical outcome of patients with carcinoma endometrium and the impact of central histopathological review on management: A tertiary cancer centre experience
    Rakhi Verma, Ajeet K. Gandhi, Madhup Rastogi, Vachaspati K. Mishra, Vikas Sharma, Akash Agarwal, Saumya Shukla, Rohini Khurana, Rahat Hadi, Anoop K. Srivastava, Nuzhat Husain
    Journal of Cancer Research and Therapeutics.2024; 20(5): 1557.     CrossRef
  • Does Prophylactic Paraortic Lymph Node Irradiation Improve Outcomes in Women With Stage IIIC1 Endometrial Carcinoma?
    Jennifer Yoon, Halle Fitzgerald, Yaqun Wang, Qingyang Wang, Irina Vergalasova, Mohamed A. Elshaikh, Irina Dimitrova, Shari Damast, Jessie Y. Li, Emma C. Fields, Sushil Beriwal, Andrew Keller, Elizabeth A. Kidd, Melissa Usoz, Shruti Jolly, Elizabeth Jawors
    Practical Radiation Oncology.2022; 12(2): e123.     CrossRef
  • Efficacy of Para-Aortic Lymphadenectomy in Early-Stage Endometrioid Uterine Corpus Cancer
    Seo-Yun Tong, Jong-Min Lee, Jae-Kwan Lee, Jae Weon Kim, Chi-Heum Cho, Seok-Mo Kim, Sang-Yoon Park, Chan-Yong Park, Ki-Tae Kim
    Annals of Surgical Oncology.2011; 18(5): 1425.     CrossRef
  • Current status in the management of uterine corpus cancer in Korea
    Nan-Hee Jeong, Jong-Min Lee, Seon-Kyung Lee
    Journal of Gynecologic Oncology.2010; 21(3): 151.     CrossRef
  • 9,165 View
  • 50 Download
  • 4 Crossref
Close layer
A Histone Deacetylase Inhibitor, Trichostatin A, Enhances Radiosensitivity by Abrogating G2/M Arrest in Human Carcinoma Cells
In Ah Kim, Jin Ho Kim, Jin Hee Shin, Il Han Kim, Jae Sung Kim, Hong-Gyun Wu, Eui Kyu Chie, Yong Ho Kim, Bo-Kyung Kim, Semie Hong, Seok Won Park, Sung Whan Ha, Charn Il Park
Cancer Res Treat. 2005;37(2):122-128.   Published online April 30, 2005
DOI: https://doi.org/10.4143/crt.2005.37.2.122
AbstractAbstract PDFPubReaderePub
Purpose

Histone deacetylase inhibitors (HDIs) are emerging as potentially useful components in anticancer therapy. In this study, we tried to confirm the radiosensitizing effect of trichostatin A (TSA) on a panel of human carcinoma cell lines and elucidate its mechanism of interaction.

Materials and Methods

A549, HeLa and Caski cells were exposed to TSA for 18 hr prior to irradiation, and the cell survival then measured using a clonogenic assay. Western blot and flow cytometric analyses, for histone acetylation, and cell cycle and apoptosis, respectively, were also performed.

Results

TSA increased the acetylation of histone H3. The pretreatment of TSA consistently radiosensitized all three cell lines. The SF2 (surviving fraction at 2 Gy) of TSA-treated cells was significantly lower than that of mock treated cells. The SER (sensitizer enhancement ratio) increased in all 3 cell lines, in concentration dependent manners. The TSA treated cells showed abrogation of radiation-induced G2/M arrest, in a concentration dependent manner.

Conclusion

The pretreatment of TSA enhanced the radiosensitivity of a panel of human carcinoma cells, which was attributed, in part, to the abrogation of radiation-induced G2/M arrest.

Citations

Citations to this article as recorded by  
  • Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer
    Yijun Xie, Di Xiao, Duo Li, Mei Peng, Wei Peng, Huaxin Duan, Xiaoping Yang
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Radiosensitizing effect of dendrosomal nanoformulation of curcumin on cancer cells
    Tahereh Jalali Varnamkhasti, Meisam Jafarzadeh, Majid Sadeghizadeh, Mahdi Aghili
    Pharmacological Reports.2022; 74(4): 718.     CrossRef
  • Pharmacological Properties of Trichostatin A, Focusing on the Anticancer Potential: A Comprehensive Review
    Abdelhakim Bouyahya, Nasreddine El Omari, Mohamed Bakha, Tarik Aanniz, Naoual El Menyiy, Naoufal El Hachlafi, Aicha El Baaboua, Mohamed El-Shazly, Mohammed Merae Alshahrani, Ahmed Abdullah Al Awadh, Learn-Han Lee, Taoufiq Benali, Mohammad S. Mubarak
    Pharmaceuticals.2022; 15(10): 1235.     CrossRef
  • Low Dose of Trichostatin A Improves Radiation Resistance by Activating Akt/Nrf2-Dependent Antioxidation Pathway in Cancer Cells
    Fengqiu Zhang, Changsheng Shao, Zhu Chen, Yalin Li, Xumiao Jing, Qing Huang
    Radiation Research.2021;[Epub]     CrossRef
  • Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
    Ying Li, Zhijun Zhan, Xuemin Yin, Shujun Fu, Xiyun Deng
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Is level of acetylation directly correlated to radiation sensitivity of cancer cell?
    Fengqiu Zhang, Zhu Chen, Changsheng Shao, Qing Huang
    Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis.2019; 813: 13.     CrossRef
  • Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53
    Manuela Terranova-Barberio, Biagio Pecori, Maria Serena Roca, Serena Imbimbo, Francesca Bruzzese, Alessandra Leone, Paolo Muto, Paolo Delrio, Antonio Avallone, Alfredo Budillon, Elena Di Gennaro
    Journal of Experimental & Clinical Cancer Research.2017;[Epub]     CrossRef
  • Histone Acetylation Induced Transformation of B-DNA to Z-DNA in Cells Probed through FT-IR Spectroscopy
    Fengqiu Zhang, Qing Huang, Jingwen Yan, Zhu Chen
    Analytical Chemistry.2016; 88(8): 4179.     CrossRef
  • Cell-based multi-substrate assay coupled to UHPLC-ESI-MS/MS for a quick identification of class-specific HDAC inhibitors
    Vincent Zwick, Claudia Simões-Pires, Muriel Cuendet
    Journal of Enzyme Inhibition and Medicinal Chemistry.2016; 31(sup1): 209.     CrossRef
  • Assessment of the Effect of Trichostatin A on HeLa Cells through FT-IR Spectroscopy
    Fengqiu Zhang, Qing Huang, Jingwen Yan, Xin Zhang, Jianxin Li
    Analytical Chemistry.2015; 87(4): 2511.     CrossRef
  • Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells
    Ahrum Min, Seock-Ah Im, Debora Keunyoung Kim, Sang-Hyun Song, Hee-Jun Kim, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, Do-Youn Oh, Tae-You Kim, Mark J O’Connor, Yung-Jue Bang
    Breast Cancer Research.2015;[Epub]     CrossRef
  • CD44 is a biomarker associated with human prostate cancer radiation sensitivity
    WeiWei Xiao, Peter H. Graham, Carl A. Power, Jingli Hao, John H. Kearsley, Yong Li
    Clinical & Experimental Metastasis.2012; 29(1): 1.     CrossRef
  • Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells
    Han Sang Kim, Sang Cheol Kim, Sun Jeong Kim, Chan Hee Park, Hei-Cheul Jeung, Yong Bae Kim, Joong Bae Ahn, Hyun Cheol Chung, Sun Young Rha
    BMC Genomics.2012;[Epub]     CrossRef
  • In vivoRadiosensitization Effect of HDAC Inhibitor, SK-7041 on RIF-1 Cell Line
    Eui Kyu Chie, Jin Hee Shin, In Ah Kim, Il Han Kim
    The Journal of the Korean Society for Therapeutic Radiology and Oncology.2010; 28(4): 219.     CrossRef
  • Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: Potential role of histone deacetylase 6
    In Ah Kim, Mina No, Jang Mi Lee, Jin Hee Shin, Jee Sun Oh, Eun Jung Choi, Il Han Kim, Peter Atadja, Eric J. Bernhard
    Radiotherapy and Oncology.2009; 92(1): 125.     CrossRef
  • Histone Deacetylase Inhibitor–Mediated Radiosensitization of Human Cancer Cells: Class Differences and the Potential Influence of p53
    In Ah Kim, Jin Hee Shin, Il Han Kim, Jin Ho Kim, Jae Sung Kim, Hong Gyun Wu, Eui Kyu Chie, Sung Whan Ha, Charn Il Park, Gary D. Kao
    Clinical Cancer Research.2006; 12(3): 940.     CrossRef
  • 12,442 View
  • 73 Download
  • 16 Crossref
Close layer
Treatment Outcome of Brain Metastasis after the Cranial Radiotherapy Followed by Fractionated Stereotactic Radiotherapy and Its Prognostic Factors
Hak Jae Kim, Semie Hong, Suzy Kim, Jin Ho Kim, Il Han Kim, Charn Il Park, Sung Whan Ha, Hong Gyun Wu, Wee Saing Kang
Cancer Res Treat. 2002;34(4):284-288.   Published online August 31, 2002
DOI: https://doi.org/10.4143/crt.2002.34.4.284
AbstractAbstract PDF
To evaluate the effectiveness of whole brain radiotherapy followed by stereotactic radiotherapy for newly diagnosed brain metastasis.
MATERIALS AND METHODS
Thirty-three metastatic brain tumors received radiotherapy to the whole brain and stereotactic radiotherapy in 25 patients. Lung carcinomas were the most common (17/25) primary tumor. The radiation dose was 30 to 40 Gy for the whole brain, with a 12 to 40 Gy boost to the metastatic foci. Survival and local control rates were determined, and the prognostic factors for survival were evaluated.
RESULTS
The overall median survival was 15 months and the actuarial survivals at 1- and 2-year were 67% and 31%, respectively. The local tumor control rate was 79%, with a median follow-up period of 9 months (2~36 months). The prognostic factors associated with survival were age, tumor size and the existence of active extracranial metastasis, with the performance status showing marginal significance. No acute or chronic complications were observed in the patients.
CONCLUSION
From our data, cranial radiotherapy followed by stereotactic radiotherapy was useful in the local control of metastatic tumors, and in the survival of patients with tumor factors, such as small size or the absence of extracranial tumor activity, and host factors, such as young age or good performance status.

Citations

Citations to this article as recorded by  
  • Prognostic Factors and Survival Outcome of Whole Brain Radiotherapy in Metastatic Brain Cancer- A Single Regional Cancer Centre Experience in North India
    Purnima Thakur, Aman Sharma, Manish Gupta, Anupama Dhiman, Jyoti Sharma
    Journal of Evolution of Medical and Dental Sciences.2019; 8(43): 3206.     CrossRef
  • Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment
    Hee-Jun Kim, Seock-Ah Im, Bhumsuk Keam, Yu-Jung Kim, Sae-Won Han, Tae Min Kim, Do-Youn Oh, Jee Hyun Kim, Se-Hoon Lee, Eui Kyu Chie, Wonshik Han, Dong-Wan Kim, Tae-You Kim, Dong-Young Noh, Dae Seog Heo, In Ae Park, Yung-Jue Bang, Sung Whan Ha
    Journal of Neuro-Oncology.2012; 106(2): 303.     CrossRef
  • 4,024 View
  • 27 Download
  • 2 Crossref
Close layer
Usefulness of Change of Telomerase Activity as a Predictive Assay for Radiation Response
Hong Gyun Wu, Young Jue Kim, Il Han Kim, Charn Il Park, Sung Whan Ha
J Korean Cancer Assoc. 2000;32(6):1109-1114.
AbstractAbstract PDF
PURPOSE
A sensitive predictive assay is necessary to determine the total radiation dose according to sensitivity of individual cancer cell lines. This study is performed to determine whether the radiation sensitivity is correlated with the changes in telomerase activity after irradiation.
MATERIALS AND METHODS
Two colorectal cancer cell lines with different radiation sensitivity were used. In order to confirm the difference in radiation sensitivity, we used a calorimetric assay. Telomerase activities were measured using the PCR-based telomeric repeat amplification protocol (TRAP).
RESULTS
We confirmed the difference in radiation sensitivity between NCI-H630 and NCI-H716. Survival fractions at 2 Gy were 0.836 for NCI-H630 and 0.317 for NCI-H716. Telomerase activity increased after irradiation with NCI-H630, which was more resistant to radiation, whereas telomerase activity decreased with NCI-H730. But dose-dependent change of telomerase activity was not confirmed.
CONCLUSION
Our results suggested that telomerase activity change after irradiation could be used as a predictive assay for radiation response. Further studies with different cell lines and tumor tissues are necessary.
  • 2,217 View
  • 17 Download
Close layer
The Effect of Adjuvant Therapy for Curatively Resected Extrahepatic Bile Duct Cancer
Won Shik Han, Sang Jae Park, Sun Whe Kim, Ki Hwan Kim, Sung Whan Ha, Yung Jue Bang, Noe Kyeong Kim, Yong Hyun Park
J Korean Cancer Assoc. 1999;31(6):1253-1260.
AbstractAbstract PDF
PURPOSE
This study was attempted to evaluate the effect of adjuvant radiotherapy and chemotherapy after curative resection of extrahepatic bile duct cancer.
MATERIALS AND METHODS
The authors performed a retrospective analysis of 57 patients with extrahepatic bile duct cancer not involving the hepatic duct confluence and curatively resected at Seoul National University Hospital between 1990 and 1995. Resection margins of all cases were confirmed pathologically as free of cancer cells. Among 57 patients, 29 received adjuvant therapy. Total 4000 cGy of external beam radiation was delivered to each. 5-fluorouracil (5-FU) was administered as a radiosensitizer. After 4 weeks of radiation therapy, 5-FU maintenance chemotherapy was started and given every 4 weeks up to 12 cycles or until evidence of relapse.
RESULTS
The overall median survival of 57 patients was 24 months. I- and 2-year overall survival rate was 73.7 and 52.6%. There was no difference in overall survival rate between adjuvant therapy group (n=29) and operation-only group (n 28). We tried to evaluate the effect on survival of adjuvant therapy according to lymph node status. Patients of Tl stage were excluded from analysis. Adjuvant therapy had no survival benefit in the lymph node positive group. But in the lymph node negative group, 1- and 2-year survival rate of patients who underwent adjuvant therapy were 89.5% and 68.4% whereas 1 and 2-year survival rate of patients in operation-only group were 57.9% and 36.8%, which was statistically significant (p=0.0278, 0.0472). And by multivariate analysis, the survival improvement of 1- and 2-year survival rate in adjuvant therapy group was due to adjuvant therapy itself.
CONCLUSION
Our trial of external beam radiotherapy combined with 5-FU chemotherapy after curative resection of extrahepatic bile duct cancer did not show improved overall survival. However the 1- and 2-year survival rate of patients with negative lymph node and advanced T stage ( > T 1) were improved in adjuvant therapy group, so adjuvant therapy may give survival benefit to a certain patient group with negative lymph node.
  • 2,849 View
  • 19 Download
Close layer
Efficacy and Optimal Condition of Radiotherapy for Metastatic Epidural Cord Compression
Il Han Kim, Suk Won Park, Eui Kyu Chie, Sung Whan Ha, Charn Il Park
J Korean Cancer Assoc. 1999;31(5):1074-1080.
AbstractAbstract PDF
PURPOSE
This study was performed to evaluate the radiotherapy effects on metastatic epidural cord compressions.
MATERIALS AND METHODS
One hundred and thirty eight cases received palliative radio- therapy (30 Gy/10 fractions) with (15) or without (123) surgical decompression. Only 36% of cases were ambulatory before treatment and 34% of cases started treatment within 3 days after symptom onset.
RESULTS
Ambulation was possible after radiotherapy in 38% of all patients and in 73% of cases who was ambulatory before treatment. But the treatment made ambulation possible for 18% of cases who was paraplegic before treatment. Complete response rate, partial response rate, minimal response rate, and progression after treatment were as follows; 7%, 37%, 53%, and 3% respectively for the motor function, 8%, 32%, 58%, and 2% respectively for the sensory function, and 17%, 17%, 65%, and 1% respectively for the autonomic function. Responses were not influenced by the primary tumor site, histology, or involved level of the spine. Good responses were associated with starting treatment within 3 days after symptom onset.
CONCLUSION
Radiotherapy gave optimal palliative effects on metastatic epidural cord compression syndrome. Maximum responses or quality of life could be obtained from prompt treatment with awareness of this syndrome in cancer patients.
  • 2,442 View
  • 12 Download
Close layer
Intracranial beta-hCG Secreting Germinoma: Clinical Significance and Radiotherapy Results
Kyung Hwan Shin, Il Han Kim, Wee Saing Kang, Sung Whan Ha, Charn Il Park
J Korean Cancer Assoc. 1999;31(2):396-402.
AbstractAbstract PDF
No abstract available.
  • 2,397 View
  • 16 Download
Close layer
Effect of blood flow on temperature distribution in microwave hyperthermia
Jong Hoon Kim, Sung Whan Ha
J Korean Cancer Assoc. 1992;24(6):813-820.
AbstractAbstract PDF
No abstract available.
  • 1,971 View
  • 15 Download
Close layer
Influence of tumor size on chemosensitivity of FSa II in combination of cyclophosphamide and radiation
Woong Ki Chung, Hyon De Chung, Sung Whan Ha, Charn Il Park
J Korean Cancer Assoc. 1992;24(1):109-124.
AbstractAbstract PDF
No abstract available.
  • 1,975 View
  • 14 Download
Close layer
The Effectiveness of Palliative Radiotherapy in the Management of Metastatic Bone Disease
Charn Il Park, Sung Whan Ha
J Korean Cancer Assoc. 1981;13(1):67-71.
AbstractAbstract PDF
To determine the effectiveness of radiotherapy for the palliation of pain in metas- tatic bone disease, we retrospectively analyzed the treatment results in 32 patients who received short-courae radiotherapy(2000 rad/I wk vs. 3000 rad/2 wk) in the dept. 'of Therapeutic Radiology, Seoul National University Hospital from Feb. 1979 to Oct. 1981. The results are as follows; 1, The incidence of metastatic bone tumor was highest in pelvis and thoracic spine, 27 and 24%., respectively. 2, Lung, kidney, stomach, breast and cervix were the primary sites, in order of frequency. 3. Overall response rate was 92% with excellent response in 48%. 4, There was no significant difference between the dose-fraction schedules of 2000 rad in 1 week and 3000 rad in 2 weeka. 6. We concluded that 2000 rad in 1 wk is at least as effective as 3000 rad in 2 weeks :in the palliation of bone metastasis.
  • 2,599 View
  • 13 Download
Close layer
5-Fluorouracil Continuous Infusion and Mitomycin-C ( FM ) Combination Chemotherapy for Metastatic or Recurrent Colorectal Cancer
Keun Chil Park, Sung Soo Yoon, Jae Hoon Lee, Seung Taek Kim, Yung Jue Bang, Noe Kyeong Kim, Jae Gahb Park, Kuhn Uk Lee, Sung Kuk Hong, Kuk Jin Choe, Soo Tae Kim, Sung Whan Ha, Charn Il Park
J Korean Cancer Assoc. 1987;19(2):101-107.
AbstractAbstract PDF
Between March, 1983 and June, 1986, 64 patients with metastatic or recurrent colorectal cancer were treated with a combination chemotherapy consisting of 5-fluorouracil (5-FV), 1,000 mg/m iv continuous infusion over .12 hours on day 1-5; mitomycin-C, 10 mg/m iv on day 1; cycled every 4 weeks. Among 46 patients with measurable lesions, none achieved complete remission and 5 (11%) achieved partial remissions. The median duration of remission was 31 weeks. Overall median survival was 49 weeks for all patients; 65 weeks for patients with remission; 51 weeks for those with stable disease; and 31 weeks for those with progressive disease, Greater response rates were observed in patient groups with age over 50, performance status 0-1, no previous history of chemotherapy, initial CEA level less than 10 ng/ml, or metastatic sites of lymph node, than in respective comparative patient groups. But, these differences did not achieved statistical significance. Toxicity was common, but generally mild to moderate and rapidly reversible.
  • 3,417 View
  • 20 Download
Close layer
The Effect of Ginkgo biloba extract on Radiation Tumor Growth Delay in C3H Mouse Fibrosarcoma
Moon Jung Cho, Chun Ja Yi, Sung Whan Ha, Charn Il Park
J Korean Cancer Assoc. 1995;27(3):482-490.
AbstractAbstract PDF
Ginkgo biloba extract(GBE), extract from leaves of Ginkgo biloba tree, is known to increase peripheral blood flow. Under the assumption that GBE would increase tumor blood flow and improve oxygen supply to the tumor and enhance radiatian sensitivity, the effect of GBE on radiation tumor growth delay was investigated. C3H mouse fibrosarcoma(FSaII), 6 mm in size, growing in the hidleg muscle of C3H mouse was used. GBE was injected i.p. once 1 hr prior to irradiation or twice 25 hrs and 1 hr prior to irradiation. Tumor growth was not influenced by GBE treatment alone. Tumor growth delay by a single dose of 50 mg/kg and l00 mg/kg of GBE plus 10 Gy of radiation was prolonged to 1.23 times and to 1.36-1.49 times when compared with 10 Gy irradiation alone. Tumor growth delay by two doses of 100 mg/kg of GBE plus 10 Gy of irradiation increased to 1.66-1.84 times(p<0.05). Radiation dose required for 3 day tumor growth delay decreased to half when two doses of 100 mg/kg of GBE was given prior to irradiation. Based on these results, it is concluded that GBE enhances radiation sensitivity of C3H mouse fibrosarcoma(FSaII) and could be a potential radiosensitizer for the malignant tumor.
  • 2,350 View
  • 20 Download
Close layer
The Effect of Hydralazine on Hyperthermic Treatment of C3H Mouse Fibrosarcoma
Woo Yoon Park, Sung Whan Ha, Charn Il Park
J Korean Cancer Assoc. 1995;27(4):671-680.
AbstractAbstract PDF
Hypoxic cells comprise l0~20% of tumor cells and are more sensitive to hyperthermia. By decreasing tumor blood flow artificially and thus increasing the hypoxic fraction in the tumor, the cytotoxic effect of hyperthermia can be increased. Hydralazine is an antihypertensive drug and its main mechanism is relaxation of the vascular smooth muscle of arterioles rather than veins. Administration of hydralazine causes a decrease in vascular resistance and an increase in blood flow in normal tissue, but since the vasculature of tumor is not responsive to such a drug, blood flow in tumors is decreased because of steal phenomenon. Thus the hypoxic fraction in the tumor is increased, and the tumor becomes more sensitive to hyperthermia. Therefore, to evaluate the hydralazine effect on hyperthermia, the tumor growth delay was investigated and the change in the hynoxic fraction of the tumor was estimated using C3H mouse fibrosarcoma(FSaII) with hypoxic fractions af usual range. In 6 mm FSaII tumors grow- ing in the dorsum of the foot, administration af 5 or l0 mg/kg of hydralazine was followed by 43`C, hyperthermia for 60 minutes. Tumor growth times (TGT) to reach a tumor volume of 500 mm(2) were 7.11+-0.84 days and 7.44+- 1.13 days for controls and 10 mg/kg of hydralazine only. TGTs for hyperthermia alone and administration of 5 or 10 mg/kg of hydralazine followed by hyperthermia were 10.34+-2.17 days, 13.38+-1.82 days and 14.47+- 0.67 days, respectively. Elongation of tumor growth delay by administration of 5 or l0 mg/kg of hydralazine in addition to hyperthermia were statistically significant (0.025
  • 2,470 View
  • 13 Download
Close layer
Radiation Therapy of Carcinoma of the Cervical Stump
Seung Jae Huh, Won Dong Kim, Yong Chan Ahn, Sung Whan Ha, Il Han Kim, Charn Il Park
J Korean Cancer Assoc. 1995;27(6):986-990.
AbstractAbstract PDF
We have reviewed 19 cases of cervical stump cancer treated at the Seoul National and Soonchunhyang University Hospital from 1983 to 1993. Patients were treated with external beam radiation and/or intracavitary radiation. Median follow up period is 39 months. The absolute disease free, and overall survival rate for all patients are 51% and 70%, respectively. Six pelvic failures and two distant metastasis were observed. Recurrences were more common in external radiotherapy only or external radiotherapy plus colpostat application group than in the external radiotherapy plus tandem and colpostat treatment group. The grade 2 complication rate was 21%(4/l9) but there were no life threatening complications. Radiation therapy is effective for the treatment of cervical stump cancer.
  • 3,088 View
  • 16 Download
Close layer
The Postoperative Adjuvant Radiation Therapy and 5-fluorouracil Maintenance Chemotherapy for Resectble Rectal Cancer
Young Hyuk Im, Chang In Suh, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim, Jae Gahb Park, Kuhn Uk Lee, Kuk Jin Choe, Sung Whan Ha
J Korean Cancer Assoc. 1996;28(2):225-236.
AbstractAbstract PDF
A phase II trial was done to evaluate the efficacy and safety of a postoperative radiation therapy and chemotherapy in patients who had undergone "curative" surgical resection for rectal adenocarcinoma. Eighty-six rectal cancer patients with pathologic stsge of Astler-Coller B1 and C were entered into this study between January 1986 to January l990. Four patients were excluded from the analysis because they were lost to fo11ow-up. Radiation therapy was begun 3-4 weeks after surgery. A total dose of 5,000 to 6,000 G was delivered in a period of 5 to 6 weeks. 5-fluorouracil(5-FU) was administered intravenously in a dose of 500 mg per square meter on the first three days of radiation as a radiosensitizer. Four weeks after radiation therapy was completed, 5-FU maintenance chemotherapy was started. 5-FU, 12mg/kg/day, was given intravenously in a bolus on days I-5 of a treatment cycle. Each chemotherapy cycle was repeated every 4 weeks upto twelve cycles or until evidence of treatment failure was documented. At the time of analysis(Aug. l994), 46 of the 82 patients(56%) had recurrence of their cancer. Of the 46 patients in whom recurrent diseases developed, 13 had locoreaional recurrences and 29 had distant metastases as the first signs of recurrences. During the 4 to 84 months(median 45 months) of follow-up period, the median time to relapse-free survival, and overall survival were 31.3 months(4.2+ -83+ months) and 71.5 months(4.2+ -83+ months), respectively. The 5-year actuarial relapse-free survival, and overall survival rates of 82 patients were 40% and 64%, respectively. The prognostic value of several variables(age, sex, performance status, pathologic stage, type of surgery, histologic subtypes, preoperative CEA level, and number of cycles of maintenance chemotherapy) was assessed. Among them, type of surgery, and number of cycles of maintenance chemotherapy(¡A6 vs. >7) were found to be significantly correlated with relapse-free interval, and age, preoperative CEA level, and number of cycles of maintenance chemotherapy were found to be significantly correlated with overall survival. The toxicities associated with radiation therapy and chemotherapy were mild and tolerable. There was no treatment-related mortality. In conclusion, the postoperative radiation therapy and 5-FU maintenance chemotherapy is effective and safe in patients with rectal cancer of Astler-Coller B2 and C stage.
  • 2,869 View
  • 19 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP